By Fineline Cube 
China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, announced that it has received clinical trial approval in the United States for its mRNA-based cancer vaccine ABO2102. The vaccine targets solid tumor patients with any of the five common mutations in KRAS.
ABO2102 Mechanism and Advantages
ABO2102 is China’s first therapeutic cancer vaccine targeting multiple KRAS mutations. Using mRNA technology, it encodes five common KRAS mutant antigens. This approach effectively activates dual immune responses involving CD8+ cytotoxic T cells and CD4+ helper T cells, enabling precise recognition and elimination of KRAS-mutated cells. Unlike small-molecule inhibitors that target only the G12C mutation, ABO2102 offers broader coverage of KRAS mutation subtypes.
Clinical Applications and Safety Profile
The vaccine is designed for off-the-shelf use and is suitable for both late-stage salvage therapy and postoperative adjuvant treatment in early-stage patients. Its favorable safety profile makes it compatible with combination therapies, including chemotherapy, radiotherapy, or immune checkpoint inhibitors, facilitating the establishment of a multidimensional synergistic tumor treatment system.-Fineline Info & Tech